OFFRE D'UNE DURÉE LIMITÉE. Obtenez 3 mois à 0,99 $/mois. Profiter de l'offre.
Page de couverture de Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

Auteur(s): Julio G. Martinez-Clark
Écouter gratuitement

À propos de cet audio

Hosted by bioaccess® CEO, Julio G. Martinez-Clark, the Global Trial Accelerators™ podcast delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia.


What You’ll Learn:

  • Speed Secrets: How to secure ethics approval in 4–6 weeks (vs. 6+ months in US/EU) using harmonized pathways like MINSA (Panama), ALIMS (Serbia), and Australia’s CTN.
  • Cost-to-Speed Hacks: Operational strategies to reduce trial budgets by 30% while maintaining FDA/EMA compliance.
  • Global Patient Access: Leverage treatment-naive populations in cardiology, rare diseases, and advanced therapies across 50+ pre-vetted sites.


Why Listen?

  • Actionable Playbooks: Reverse-engineer success stories from startups that enrolled cohorts 50% faster and secured Series B funding 12–18 months early.
  • Regulatory Intel: Stay ahead of shifting LATAM, Balkans, and APAC guidelines with on-the-ground experts.
  • Future-Proof Insights: Explore decentralized trials, AI-driven recruitment, and post-trial commercialization in $1B+ markets.

“bioaccess®’s Serbia site activated in 8 weeks-9 months faster than our EU delay.


This podcast is why we partnered with them.”
– Digital Health Startup CEO


New episodes drop weekly. Subscribe to unlock your shortcut to global trial velocity.


Brought to you by bioaccess® – Turning “anywhere” into accelerated FDA/EMA submissions since 2010.

© 2025 Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere Gestion et leadership Hygiène et mode de vie sain Troubles et maladies Économie
Épisodes
  • David Kraemer, Founder & Managing Member at 10 || 2 Capital Partners

    David Kraemer, Founder & Managing Member at 10 || 2 Capital Partners
    Oct 30 2025

    In this episode, we sit down with David M. Kraemer, Founder of a boutique investment bank and former Vice President at Merrill Lynch and Wilshire Consulting. With deep experience across public and private markets, David shares insights on capital formation, innovation, and navigating complex investment landscapes.

    From biotech and MedTech to AI, robotics, and venture capital, his perspective bridges finance and technology in today’s fast-changing world. Tune in to hear how he’s built global partnerships and what drives his success in the ever-evolving world of investment and entrepreneurship.

    Voir plus Voir moins
    31 min
  • Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc

    Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc
    Oct 10 2025

    Today we’re joined by Dr. Joseph M. Palumbo, a physician-scientist, mentor, and therapeutics developer with more than three decades of leadership in psychiatry, neurology, and neurodegenerative research.

    Dr. Palumbo has led groundbreaking work across the full R&D spectrum—from preclinical innovation to global drug approvals—advancing programs valued at over $1 billion. He has held senior leadership roles as Global Head of Psychiatry at Johnson & Johnson, Vice President & Fellow at Mitsubishi Tanabe Pharma, and Chief Medical Officer at Zynerba and BioVie.

    His contributions include several successful FDA approvals, including Risperdal Consta®, Invega®, Invega Sustenna®, and Radicava®. At BioVie, he currently serves as Executive Vice President, Head of R&D, and Chief Medical Officer, as well as Principal Investigator on a $13 million U.S. Department of Defense study on Long COVID.

    A Life Fellow of the American Psychiatric Association and Fellow of the American Neurological Association, Dr. Palumbo brings a rare combination of scientific innovation and executive leadership—bridging translational medicine, enterprise strategy, and patient impact.
    Voir plus Voir moins
    36 min
  • Nicholas Kadysh, CEO at PharmAla Biotech

    Nicholas Kadysh, CEO at PharmAla Biotech
    Sep 26 2025

    In this episode, we welcome Nicholas Kadysh, CEO of PharmAla Biotech, the company pioneering GMP MDMA production and named the top-performing stock on the Canadian capital markets in 2023 by The Market Herald.

    As Chair of Psychedelics Canada, Nicholas has been instrumental in advancing legal and ethical standards, building strong relationships with government, and shaping a regulatory landscape where healthcare innovation can thrive. His leadership has also been recognized by The Peak, which honored him in 2023 for emerging leadership in healthcare.

    Tune in for an insightful conversation on the future of psychedelic medicine, biotech innovation, and the policies driving change in healthcare.

    Voir plus Voir moins
    33 min
Pas encore de commentaire